JMP Securities Issues Pessimistic Forecast for Hookipa Pharma (NASDAQ:HOOK) Stock Price

Hookipa Pharma (NASDAQ:HOOK) had its target price dropped by stock analysts at JMP Securities from $24.00 to $7.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ price target points to a potential upside of 225.58% from the stock’s previous close.

Separately, Royal Bank of Canada reduced their price target on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th.

Hookipa Pharma Stock Down 6.5 %

Shares of Hookipa Pharma stock opened at $2.15 on Thursday. The company has a market cap of $25.92 million, a P/E ratio of -0.58 and a beta of 0.84. The firm’s 50 day moving average price is $3.90 and its 200-day moving average price is $5.56. Hookipa Pharma has a 52-week low of $2.08 and a 52-week high of $11.30.

Institutional Trading of Hookipa Pharma

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in shares of Hookipa Pharma by 85.8% in the 1st quarter. Acadian Asset Management LLC now owns 882,262 shares of the company’s stock valued at $627,000 after acquiring an additional 407,532 shares during the period. Renaissance Technologies LLC grew its stake in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the last quarter. Ikarian Capital LLC acquired a new position in shares of Hookipa Pharma in the third quarter valued at about $228,000. Finally, Virtu Financial LLC purchased a new position in shares of Hookipa Pharma in the first quarter worth about $31,000. 63.88% of the stock is currently owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.